🇺🇸 FDA
Pipeline program

TPST-1495 twice daily

TPST-1495-001

Phase 1 small_molecule completed

Quick answer

TPST-1495 twice daily for Solid Tumor is a Phase 1 program (small_molecule) at Tempest Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Tempest Therapeutics
Indication
Solid Tumor
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials